More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
A randomized study of more than 450 patients with persistent atrial fibrillation is now underway. All patients have been treated, and their outcomes will be tracked for 12 months.
“There is a crucial need to develop synthetic vascular graft materials that will increase the rate of long-term functions,” one researcher said. Could materials derived from seaweed help fill that need?
The healthcare industry accounts for close to 30% of global helium consumption, with MRI equipment needs accounting for a significant portion of that figure.
Capping the RSNA 2022 conference in Chicago, an RSNA editorial board has selected a 3D cinematic rendering as the single best radiological image of the year.
Stanford researchers have created synthetic yet highly realistic chest X-rays by customizing an open-source AI model called Stable Diffusion for rendering text as images.
The new study, published in Circulation, represents a collaboration between specialists from a variety of facilities, including Cleveland Clinic and the University of Arizona.
